NuScale faces long timelines, restrictive ENTRA1 deals, 2030 EBITDA priced in, and Fluor stake risks, limiting near-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback